BionTech 从 Uppen license专利覆盖不只疫苗,2018年的协议还有很多都在umbrella里 Penn Agreement In October 2018, BioNTech RNA entered into a collaboration and license agreement with the Trustees of the University of Pennsylvania regarding the development and commercialization of certain mRNA vaccines and mRNA diagnostics for the diagnosis, detection, evaluation, prophylaxis and treatment of infectious diseases. We refer to this agreement as the Penn Agreement. Under the Penn Agreement, BioNTech RNA and Penn agree to collaborate with respect to research and development activities and are obligated to use commercially reasonable efforts to develop products that use formulated mRNAs encoding one or more immunogens for 10 disease indications in the field of infectious diseases (each, a Penn Product). Penn is responsible for all research and development work up to completion of studies enabling an IND as well as IND-supporting preclinical work, and BioNTech RNA is responsible for the manufacture of mRNA amounts to support the preclinical and IND-enabling studies. If a Penn Product developed under the research program achieves certain acceptance criteria for a specified indication, BioNTech RNA has the right to obtain an exclusive worldwide license under Penn’s patent rights (and a non-exclusive license under Penn’s know-how and materials) to research, develop, make, use or commercialize Penn Products in such indication. Under the Penn Agreement, Penn retains certain rights to conduct and authorize non-commercial third-party research, educational and patient care activities under any licensed intellectual property. Moreover, the license granted by Penn is subject to certain rights granted to the U.S. government in connection with government funding provided by the United States, including the requirement that products that result from intellectual property funded by the U.S. government that are sold in the United States be substantially manufactured in the United States. BioNTech RNA has an obligation to use commercially reasonable efforts to clinically develop, obtain regulatory approval for and commercialize at least one Penn Product for each indication licensed under the Penn 178
Table of Contents Agreement. Moreover, BioNTech RNA is obligated to achieve certain clinical and regulatory milestones within specified time periods, and its failure to do so would provide Penn the right to terminate the Penn Agreement on an indication-by-indication basis. BioNTech RNA paid to Penn an upfront fee of $5 million to fund research activities and has agreed to pay Penn additional funds through quarterly payments, not to exceed an aggregate of $15 million, upon depletion of the previously advanced funds. Under the Penn Agreement, BioNTech RNA also agreed to pay Penn an annual alliance management fee. In addition, if any Penn Product is covered by a Penn patent, BioNTech RNA will pay to Penn development and commercialization milestone payments up to $44.4 million for each Penn Product licensed under this agreement and royalties in a low-single digit percentage on net sales of all Penn Products licensed under the Penn Agreement. Further, Penn will receive a percentage of any income from sublicenses BioNTech RNA grants to third parties, subject to certain caps set forth in the Penn Agreement. BioNTech RNA has the sole responsibility for and decision-making authority over clinical development and commercialization activities relating to any Penn Product arising from the collaboration. BioNTech RNA is also responsible for the manufacture of mRNA to support clinical development and commercialization efforts. The Penn Agreement remains in effect until the expiration of the last Penn patent covering any licensed Penn Product or developmental product candidate. BioNTech RNA may terminate the Penn Agreement for convenience in its entirety or on an indication-by-indication basis upon 90 days’ prior notice to Penn. The Penn Agreement also grants both parties termination rights for uncured material breaches, including for BioNTech RNA’s failure to achieve its obligations to achieve certain diligence milestones, and insolvency.
🔥 最新回帖
大V来洗啦,可惜睁眼说瞎话水平太低。。。
估计是国内老人家来当小白鼠
🛋️ 沙发板凳
换个名 就安全了,还能增强民族自豪感,若干年后在书写历史的时候可以说2019年来自德特里克堡的美军病毒给人类带来了浩劫,中国复星的mRNA疫苗拯救了全世界!
你那个是资本主义国家的标准 不符合中国国情
正想说这不是Pfizer三期临床试验的数据吗?复星没有参与这个三期的试验,至少引用一下Pfizer吧。
这有啥吐槽的, Pfizer本来就不是这个疫苗的发明者,复星本来也就是 BioNTech的投资方
他说参与就参与了,反正也不会有人反驳。普通人会觉得这是比辉瑞更好的疫苗。
临床是辉瑞和BioNtech做的,复星前期做了动物实验,还不是同一个东西,复星开始做的是BNT162b1,做的是一期,后来就不做了,这次直接拿辉瑞的另一个东西的三期数据来讲。你说有啥吐槽的?
投资就投资,为啥总强调“合作开发”? 并且不提一句另一个真正合作开发公司(虽然目前还转卖着人家生产的产品,用着人家的临床数据) ?
BNT62b2 和复兴一毛钱关系都没有,这叫舞池加碰瓷,不过强国无耻惯了早无所谓了
这个是全民弯道超车的withdrawal。
看到任何外资有关的新闻,中国国民只会微微一笑,默认在共产党的英明领导下,外企不得不用技术换市场、屈辱接受技术转让的条件。
如果不提合作开发、暗示自己好像也把技术弄到手了,那反而会政治不正确、被中国民众认为是洋买办、卖国汉奸。
另外再告诉大家一个很机密的事:本人参与了F35战机的研发和生产,因为本人拥有Lockheed Martin的股票,我投资了!
哦对了,复兴药业拥有BioNtech大约0.6%的股份。。。。
WM反反复复就那么几句话:1、复兴参与投资了,也算参与研发了;2、疫苗技术是biontech的,辉瑞和复兴一样,就是一个代工厂;3、辉瑞就做做试验,一点技术含量都没有。。。。 都懒得反驳了,你永远叫不醒装睡的人。他们不是不知道真相,而是任务需要。
原来面瘫疫苗是复星研发的
辉瑞疫苗面瘫,复星疫苗亚克西 😆
辉瑞确实做实验证明了疫苗有效性,但是技术是biontech的,biontech愿意让复兴用有什么问题?
来洗地了,复星没和辉瑞签协议干嘛用人家辉瑞的临床数据往自己脸上贴金呢。都做的不是同一个东西,你用别人的数据,你说有什么问题?
差不多是这样,辉瑞也不是说没有技术含量,但是技术本来就是biontech的,不知道为啥有些大妈总是在纠结这些
难道不是你们自己“双标” 嘛? 年初天天黑mrna 现在有用了又得绕回来,把你们最喜欢用的“双标” 送回给你
自扇嘴巴过多少次了,找个人负责一下就伟大了呗
科学素养是啥?不忘初心,初心包括科学素养这词吗?
从发明到成药失败率超过90%,成本几个亿。您说辉瑞是什么角色。
你要求太高了,强国各种剽窃成风,还指望他们给被剽窃的人credit,简直就是痴心妄想。
不仅抄袭,而且是copy后走别人的路让别人无路可走。劣质产品倾销全世界浪费资源破坏环境。最后还劣币驱除良币。
这种Pfizer不参与技术转让,他们重新做的话是不是还需要从clinical做起?
你想说明什么?所以抄袭不提被抄袭者是没有办法的事?政府要求他们这么做?是药厂贱还是政府贱?
也有一定道理,大环境那样,屁民们都自我censor讨好上面。从上到下都做假。
骗的偷的会很快瓦房店化。
所以赵婷说的话有什么错?
复兴老总有些恶心人的言论,自己写的长文,也不是党逼着他写的吧,也别都怨到政策上,一丘之貉
难道有谁说她说错了吗?lol
所以才更加让人恼羞成怒
颠倒黑白的土共
没记错的话?
你敢说Biontech疫苗只有11个专利,而且10个都是宾大的?
bioNTech自己就有很多相关专利,不过看起来很多还是patent application https://www.citizen.org/article/biontech-and-pfizers-bnt162-vaccine-patent-landscape/
制作辉瑞疫苗的patent11个有10个是upenn的, 你说的那些biontech自己申请的有不是core tech, 不少是pending用其他application或者说modified version
发明者的定义错了。从research的角度出发,在实验室里做出一个prototype固然不容易。但是把它产品化,量产化,中间所要经历的困难和面临的各种问题是指数级的,何况还要涉及种种资金,产业链,政策,法规,市场等等。
他们就是胡搅蛮缠,诡辩。他们意思复兴做了0.1%的贡献(投资和分销),然后说复兴参与了,辉瑞没有做100%的贡献,(技术是bioetech的,其实也不是biontech的,这个技术来自于美国宾大,卖给了biontech和moderna),只做了临床和生产,这些都不能算贡献,所以说这疫苗不是辉瑞的。 这个疫苗官方名称叫pfizer-biontech,不知道怎么能洗成和辉瑞无关,我也是服气!!
你这个只能说明Kariko本人作为co-inventor的专利有11项,其中有10项是属于宾大的,并不能说明biontech疫苗只有11项专利,其中10项属于宾大,也不能说明这10项专利都用于了biontech疫苗,更不能说明这10项专利是核心专利。
找找资料来证明biontech新冠疫苗只用了11项专利吧。
一个疫苗怎么可能只有11个专利?人家意思只不过表达一下这个技术不是完全biontech发明的,说的是有11个相关专利里面10个是宾大的,你装作故意听不懂,然后鸡蛋里挑骨头。
mrna技术是疫苗底层技术,就好像计算机语言,别人用Python开发出的产品专利和技术都是别人的,不存在技术来自于宾大。
制作辉瑞疫苗的patent11个有10个是upenn的, 你说的那些biontech自己申请的有不是core tech
再仔细读一下是啥意思,中文不好吗?
你知道辉瑞疫苗涉及多少专利,哪些专利又是核心专利吗?你和那位层主都不知道吧?
大家争论的核心不是biontech的贡献,是辉瑞有没有贡献。没有人抹杀biontech的贡献,是有人说这个疫苗跟辉瑞无关。
这不重要
我就事论事而已
我也很好奇biontech疫苗一共涉及多少项专利,哪些是核心专利
辉瑞有多少专利,你知道?
不知道
你知道指点下吧?说说biontech新冠疫苗一共涉及多少项专利,有多少是辉瑞的,多少是biontech的,多少是宾大或其他公司的,哪些是核心专利。
三期蒜毛?比如科兴灭活要命名成科兴巴西疫苗吗?辉瑞做个三期就非要冠名太搞笑了
不懂啊。。。这些是核心专利吗?这么多upenn的,都是十几年前的,专利管几年?这些专利卖给辉瑞了吗?
辉瑞就只做了三期试验吗?这个疫苗是Pfizer-BioNtech共同研发的。还真冠名了叫Pfizer-BioNtech vaccine. 从临床设计,递交审批到量产。复星用人家的数据不引用还有理了。
哈哈,你喷我没有意义啊,我只是表达下个人的看法,你自己觉得是什么就是什么呗🙂
这个你有功夫可以自己查,看你在这上蹿下跳群情激昂,以为你是内行
什么叫非要冠名??人家who和fda文件上就是Pfizer-biontech疫苗,你也知道光做三期不能冠名,所以pfizer做的比你认为的多多了,疫苗名字pfizer还排在biontech前面,你们口中的biontech疫苗只是不正规的简称,当然Pfizer疫苗也是简称,官方文件这两个都不存在的,官方文件只有一个名字,叫pfizer-biontech
按你的逻辑,三期都不算啥。那复星等人家做完了三期,拿了一个成功了疫苗做一个中国的二期桥接试验,转身就变成复星疫苗了。你会觉得更搞笑吧
复星连3期都不做的,看来是没脸冠名了
你上蹿下跳吧,有干货就拿出来,没干货一边儿去。
顺便教教你群情激昂是什么意思。
群情激昂 [qún qíng jī áng]
群情激昂,汉语成语,拼音是qún qíng jī áng,指大家的情绪都很激动和高昂。
呦。说疫苗的事儿呢,开始查成语词典了?
说的是你自己吧,这么多帖子里都有你,都成抬头看id了。不明白你每次跟大家杠能拿多少钱?说来说去,你拿点干货?正常人在美国的,没事天天怼美国,谁能相信你不是翻墙的?要不就是分裂
BionTech 从 Uppen license专利覆盖不只疫苗,2018年的协议还有很多都在umbrella里
Penn Agreement In October 2018, BioNTech RNA entered into a collaboration and license agreement with the Trustees of the University of Pennsylvania regarding the development and commercialization of certain mRNA vaccines and mRNA diagnostics for the diagnosis, detection, evaluation, prophylaxis and treatment of infectious diseases. We refer to this agreement as the Penn Agreement. Under the Penn Agreement, BioNTech RNA and Penn agree to collaborate with respect to research and development activities and are obligated to use commercially reasonable efforts to develop products that use formulated mRNAs encoding one or more immunogens for 10 disease indications in the field of infectious diseases (each, a Penn Product). Penn is responsible for all research and development work up to completion of studies enabling an IND as well as IND-supporting preclinical work, and BioNTech RNA is responsible for the manufacture of mRNA amounts to support the preclinical and IND-enabling studies. If a Penn Product developed under the research program achieves certain acceptance criteria for a specified indication, BioNTech RNA has the right to obtain an exclusive worldwide license under Penn’s patent rights (and a non-exclusive license under Penn’s know-how and materials) to research, develop, make, use or commercialize Penn Products in such indication. Under the Penn Agreement, Penn retains certain rights to conduct and authorize non-commercial third-party research, educational and patient care activities under any licensed intellectual property. Moreover, the license granted by Penn is subject to certain rights granted to the U.S. government in connection with government funding provided by the United States, including the requirement that products that result from intellectual property funded by the U.S. government that are sold in the United States be substantially manufactured in the United States. BioNTech RNA has an obligation to use commercially reasonable efforts to clinically develop, obtain regulatory approval for and commercialize at least one Penn Product for each indication licensed under the Penn 178
Table of Contents Agreement. Moreover, BioNTech RNA is obligated to achieve certain clinical and regulatory milestones within specified time periods, and its failure to do so would provide Penn the right to terminate the Penn Agreement on an indication-by-indication basis.
BioNTech RNA paid to Penn an upfront fee of $5 million to fund research activities and has agreed to pay Penn additional funds through quarterly payments, not to exceed an aggregate of $15 million, upon depletion of the previously advanced funds. Under the Penn Agreement, BioNTech RNA also agreed to pay Penn an annual alliance management fee. In addition, if any Penn Product is covered by a Penn patent, BioNTech RNA will pay to Penn development and commercialization milestone payments up to $44.4 million for each Penn Product licensed under this agreement and royalties in a low-single digit percentage on net sales of all Penn Products licensed under the Penn Agreement. Further, Penn will receive a percentage of any income from sublicenses BioNTech RNA grants to third parties, subject to certain caps set forth in the Penn Agreement. BioNTech RNA has the sole responsibility for and decision-making authority over clinical development and commercialization activities relating to any Penn Product arising from the collaboration. BioNTech RNA is also responsible for the manufacture of mRNA to support clinical development and commercialization efforts. The Penn Agreement remains in effect until the expiration of the last Penn patent covering any licensed Penn Product or developmental product candidate. BioNTech RNA may terminate the Penn Agreement for convenience in its entirety or on an indication-by-indication basis upon 90 days’ prior notice to Penn. The Penn Agreement also grants both parties termination rights for uncured material breaches, including for BioNTech RNA’s failure to achieve its obligations to achieve certain diligence milestones, and insolvency.
不走正常流程这次疫苗体现非常明显,药和疫苗都是做完临床再使用,就像这次新冠疫苗,紧急情况下使用也是三期完成了再用,而中国的疫苗老年人组基础病组几乎没有数据,但是国内外到处给老人打,不知道为什么非要这样做
估计是国内老人家来当小白鼠